Summary
Overview
Work History
Education
Skills
LANGUAGES
Timeline
Generic

ANNIE SYNTOSI

Basel

Summary

Strategic and impact-driven Global Access & HEOR Associate Director with over 8 years of experience shaping and executing value-based launch strategies for innovative pharmaceutical products across global markets. Proven leadership in cross-functional teams, pricing & access strategy development, and commercial operations in LMICs. Adept at translating complex data into actionable insights that drive equitable health access and sustainable business outcomes. On a journey towards empathetic & inclusive leadership, passionate about global health equity, innovation, and launch excellence.

Overview

9
9
years of professional experience

Work History

Launch Strategy Commercial Lead (Rotation)

Novartis Pharma AG
04.2025 - Current
  • Leading go-to-market strategy and launch planning for 3 Key SSA markets.

Global Access & HEOR Ass. Director- Malaria & Sickle Cell Disease

Novartis Pharma AG
07.2022 - Current
  • Leading access, pricing & HEOR strategy & localization for Sickle Cell Disease and Malaria assets, integrating commercial, medical, and regional insights
  • Implementing innovative financing strategies, to scale patient reach in SSA
  • Secured reimbursement in Ghana and Tanzania; supported market readiness in EU, US, SSA, and India.
  • Co-led parts of the commercial strategy, incl. business case for ≈1M units at-risk, and long-term competitive planning
  • Managed crisis response post-Phase 3 readout; ensured payer alignment and regional continuity
  • Informed FDP with payer-driven analytics for an asset at risk
  • Led international reference pricing assessments and risk mitigation strategies
  • Developed early pricing frameworks to inform FDP & the commercial assessment

Global Associate Director - RWE & HEOR

Novartis Pharma AG
10.2018 - 06.2022
  • Led the RWE strategies for 6 brands, supporting payer negotiations, leading to commercial claims
  • Co-led integrated evidence plans and the creation of the value stories for key ophtha brands, aligning RWE with access and launch strategies
  • Designed and delivered an HEOR (cost-of-blindness) study across 7 countries, used to inform our gene therapy’s value proposition
  • Delivered HTA-ready NISs and drove RWD strategy for submissions and reimbursement
  • Contributed to EUnetHTA assessment for Beovu

Region Europe Assignment - Value & Access CRM

Novartis Pharma AG
10.2021 - 05.2022
  • Developed healthcare system engagement and population health strategies for Leqvio launch, with a focus on France and EU5 alignment.
  • Trained local teams on access, RWE, and HEOR to strengthen launch.

Research Associate

Amaris Consulting
01.2018 - 07.2018
  • Delivered all market & HEOR launch material & provided strategic brand support

Research Placement

World Health Organization
06.2016 - 09.2016
  • Contributing author to the WHO Report: "Monetizing Informal Care: Methodological Approaches"

Education

Master of Science - Global Health

London School of Economics & Political Science
01.2017

Bachelor of Science - Nutrition

University of Nottingham
01.2015

Skills

  • Strategic planning and launch strategy
  • Access & HEOR strategy & localization
  • Real-World Evidence (RWE) and HEOR
  • Cross-functional team leadership

LANGUAGES

Greek
Bilingual or Proficient (C2)
English
Bilingual or Proficient (C2)
German
Intermediate (B1)

Timeline

Launch Strategy Commercial Lead (Rotation)

Novartis Pharma AG
04.2025 - Current

Global Access & HEOR Ass. Director- Malaria & Sickle Cell Disease

Novartis Pharma AG
07.2022 - Current

Region Europe Assignment - Value & Access CRM

Novartis Pharma AG
10.2021 - 05.2022

Global Associate Director - RWE & HEOR

Novartis Pharma AG
10.2018 - 06.2022

Research Associate

Amaris Consulting
01.2018 - 07.2018

Research Placement

World Health Organization
06.2016 - 09.2016

Bachelor of Science - Nutrition

University of Nottingham

Master of Science - Global Health

London School of Economics & Political Science
ANNIE SYNTOSI